
#48: The science-backed diet-and-fasting blueprint for a longer, healthier life
Dr. Nickhil Jakatdar has been working at the cutting edge of preventive health and longevity over the last 10 years with the 3 D's – data, doctors, and dietitians – to go from being diagnosed with heart disease at the age of 41, to now having all his blood markers and body measurements in the green and his epigenetic biological age at 41 while his chronological age is 51. With a Ph.D. in Electrical Engineering and Computer Science from UC Berkeley and more than 60 patents to his name, Dr. Jakatdar has always believed in a scientific, data driven and practical approach to solving problems. He has founded or run 5 startups in the areas of semiconductors, consumer mobile video and molecular diagnostics and serves on the Advisory Boards of the South Asian Heart Center in California, the Center for Information Technology Research in the Interest of Society (CITRIS), has been a TEDx speaker and has been the youngest recipient of the esteemed UC Berkeley Distinguished Alumni Award. LESS ... MORE
'What's the most effective diet and fasting framework that helps improve both lifespan and health span?'
This is a question I get asked a lot, and one that I have spent many years trying to research and experiment with. With so many diets and fasting strategies out there, it's hard to separate trends from what's actually backed by science. In today's post #48, I provide my conclusions and recommendations, along with the clinical evidence supporting them. As always, while each of our bodies react differently and therefore need to be optimized for accordingly, the Evidence Based Medicine (EBM) studies I quote have been done across large populations. For those that want the conclusion without reading further, here they are: a) base your meals on Mediterranean principles, b) eat in a 10 AM–7 PM window, c) add in a once or twice a month 24 hour fast, and d) avoid extremes.
A Quick Note on Evidence Based Medicine (EBM)
Evidence-Based Medicine or EBM—the practice of making health decisions based on the best available scientific research out there. But not all the millions of studies published are equal, so scientists rank them by strength.
Sort A = High-quality evidence (large, consistent clinical trials or meta-analyses). Most trustworthy.
Sort B = Moderate-quality evidence (some good studies, but with mixed results or smaller scale).
Sort C = Low-quality evidence (based on expert opinion, early trials, or animal studies).
There is also a metric called I² (I-squared), which tells us how much the results vary across the numerous studies in a meta-analysis.
I² < 25% means the different studies mostly agree = reliable evidence.
I² > 50% means the different studies had different results = use with caution.
Together, Sort level and I² help us separate what's truly proven from what's still speculative. This combination—EBM Sort A with I² < 25%—is what I consider the gold standard. When evidence meets that bar, it makes my short list.
The clear winner: Mediterranean diet
EBM Sort A, I² = 9%
If there's one eating pattern that consistently wins across cultures and decades of studies, it's the Mediterranean diet.
In a meta-analysis of over 1.5 million people, those who followed this diet saw a 9% reduction in all-cause mortality. The PREDIMED trial, one of the most robust dietary studies ever conducted, showed a 30% drop in cardiovascular events in participants eating a Mediterranean-style diet enriched with olive oil or nuts.
The key ingredients of a Mediterranean diet include vegetables, legumes, olive oil, fish, nuts, whole grains—and very little sugar or processed food. It's sustainable, flavorful, and deeply rooted in how some of the world's healthiest populations eat. For those interested in the Indian version of the classic Mediterranean diet, check out the video interview I did with renowned clinical nutritionist, Dr. Geeta Dharmatti, on the Longevity Lab Community video meet series. If you want to watch snippets from the talk, you can do it here or join the Longevity Lab Community to watch the interview or to review the summary show notes
Coupled with intermittent fasting (10am to 7pm eating window)
EBM Sort A, I² = 22%
Now let's talk about when you eat. I personally follow intermittent fasting (IF) with a 10 AM to 7 PM eating window, giving my body ~15 hours of fasting each night. This schedule fits my lifestyle while tapping into powerful metabolic benefits.
In a 2020 meta-analysis with I² = 22%, IF was shown to significantly reduce fasting glucose, insulin, body weight, and inflammation—even without reducing calorie intake. That's a big deal. IF works not just because you eat less, but because you give your body time to rest, repair, and rebalance.
IF activates AMPK (your cell's energy regulator) and suppresses mTOR (your body's growth and aging switch), while enhancing autophagy, the process of cleaning out damaged cellular parts. These pathways are at the core of what we know about aging and healthspan. If these words sound too scientific, don't worry about it. I'll be doing a post on explaining these in simple terms because an understanding of these mechanisms help with understanding how our bodies behave during fasting vs. when we are well fed, and both have important roles to play in longevity and healthspan.
And/or calorie restriction (without malnutrition) EBM sort A, I² < 20% (CALERIE Trial)
Calorie restriction (CR)—eating about 10%–15% fewer calories than your body burns—has been shown to extend lifespan in every species studied. In humans, the CALERIE trial found that two years of mild CR improved insulin sensitivity, lowered inflammation, and improved cardiovascular biomarkers—even among healthy, non-obese individuals.
But it comes with caveats: reduced energy, muscle loss, and risk of nutrient deficiencies if you're not careful. For those of us over 50, it's essential to prioritize protein and strength training if exploring this strategy. Alternatively, intermittent fasting can deliver many of the same benefits without constant calorie counting.
Diets with weak or mixed evidence Some popular diets just don't hold up under rigorous scientific review. I cover them as well so as to provide the rationale behind why they don't make the cut. Here's how they rank:
1. Ketogenic diet EBM sort B, I² = 38%
Keto has proven benefits for epilepsy and can improve insulin resistance and weight loss in type 2 diabetes. But for healthy individuals focused on longevity, the evidence is thin. No long-term studies show a reduction in mortality or aging-related decline. High saturated fat intake, low fiber, and nutrient gaps are concerns. In short: therapeutic, but not necessarily longevity-enhancing for most reasonably healthy individuals.
2. Paleo/ carnivore diets EBM Sort B, I² > 40%
These diets cut out processed food, which is good—but they also eliminate fiber-rich, longevity-promoting foods like legumes and whole grains. Most studies are short-term and observational. No strong Randomized Controlled Trials or RCTs support these diets for long-term healthspan.
3. Ultra-processed vegan diets EBM sort B, I² = 35%–50%
Whole-food plant-based diets are associated with lower mortality and disease risk—when done right. But highly processed vegan diets (mock meats, sugary snacks) don't offer the same benefits. Quality matters more than the label. If you are on a vegan diet, make sure you keep a close eye on the quality of your carbs.
My summarized recommendations:
Here's what I follow—and recommend—if health span and longevity are your goals:
Base your meals on Mediterranean principles: veggies, legumes, olive oil, fish, whole grains, and nuts. I don't eat much fish but I do have chicken (grilled usually) and some amount of unflavored, unsweetened yogurt. Eat in a 10am–7pm window to give your body time to repair overnight. While I follow a 15 hour fasting window, even a 12-14 hour window is fine. Make sure it's practical to fit within your lifestyle, but avoid eating too much after sunset, since our circadian rhythm is a big driver of hormone balance. Add in a once-a-month or twice-a-month 24 hour fast to trigger deeper autophagy and mitochondrial rejuvenation. It is critical to not overdo it to ensure no muscle mass loss, and to avoid thyroid dysregulation. Avoid extremes. Diets that exclude major food groups often don't stand up to long-term evidence.
Final thought
Longevity is about combining the best of what modern science and ancestral wisdom agree on—and doing it consistently. Eat well. Eat smart. Give your body time to recover. And build strength—this will stand you in good stead for decades to come.
Facebook Twitter Linkedin Email Disclaimer
Views expressed above are the author's own.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
9 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.


Time of India
an hour ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.


Time of India
2 hours ago
- Time of India
DCA seizes stocks of banned medicated soap
1 2 3 H yderabad: The Drugs Control Administration (DCA) officials in Karimnagar conducted a raid and seized stocks of a banned medicated soap that was being sold illegally on Sunday. Acting on a tip-off, they raided PLN Pharma Distributors in Karimnagar and found Dr Ethix's MediSkin Medicated Soap, which contains the prohibited combination of permethrin, cetrimide and menthol. The soap had been illegally manufactured by Maxwell Pharma in Solan, Himachal Pradesh, for the Chennai-based company Dr Ethix Products and Services. According to officials, this specific drug combination was banned by the central government in 2018 due to a lack of therapeutic justification and public health concerns. The prohibition covers the manufacture, distribution and sale of the soap for human use across the country. Further investigation is being carried out on the drug samples collected.